Multiple Myeloma Trends: Treatment Shifts and Market Expansion Forecast

Multiple myeloma is a cancer originating from clonal plasma cells that accumulate in the bone marrow. These cancerous cells disrupt normal blood cell production and secrete excessive monoclonal paraproteins, leading to severe organ damage. Despite being incurable, new therapeutic discoveries are significantly enhancing disease outcomes and patient survival.

📈 Get a snapshot of key insights in the Multiple Myeloma Infographic .

Epidemiological Trends

In 2023, the incidence of multiple myeloma across the 7MM was estimated at around 75,000 cases, with a continued rise expected. The disease is notably more prevalent in men, with over 50% of US cases occurring in males. Age is a risk factor, with the majority of cases (70%) found in patients aged 65 and older. Notably, about half of the patients are ineligible for transplant, and many eligible individuals forego the procedure due to various barriers.

📊 Gain detailed insights into epidemiological segmentation in the Multiple Myeloma Market Report .

Market Snapshot and Drivers

The treatment market for multiple myeloma in the 7MM stood at USD 21 billion in 2023, fueled by the approval of new therapies. Key additions like TALVEY and ELREXFIO are transforming outcomes for patients with relapsed or refractory disease. Moreover, the use of DARZALEX-based combinations in first-line treatment—regardless of transplant eligibility—marks a strategic evolution in treatment protocols.

💡 Explore the latest therapeutic advancements in the Multiple Myeloma Drug Pipeline .

Challenges and Pipeline Innovation

Despite strong market growth, high therapy costs limit accessibility. additionally, the expiration of patents on blockbuster drugs such as DARZALEX and REVLIMID is expected to intensify generic competition.

Biopharma giants such as Celgene, Sanofi, Pfizer, AbbVie, Janssen, Takeda, and Bristol-Myers Squibb remain actively engaged in driving innovation within this space.

📥 Access the full Multiple Myeloma Report by DelveInsight .